Brenda Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brenda Zhou has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Charles Clifton Wykoff
Retina Consultants of Texas, Houston, Texas
4 shared publications - Alexander M. Rusakevich
Retina Consultants of Houston, Houston, Texas
2 shared publications David M. Brown
Retina Consultants of Houston, Houston, Texas, USA; Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas, USA
2 shared publicationsTien P. Wong
2 shared publicationsAlexander M. Rusakevich
Retina Consultants of Houston, Houston, Texas, USA
1 shared publicationAmanda Zhou
Institute for Cancer Genetics, and Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, 1130 St Nicholas Avenue, New York, NY 10032, USA
1 shared publication
Latest Publications
- 1 February 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 210, 86-96
Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up
- 1 February 2020
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 210, 86-96
Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up
- 1 December 2019
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (12) , 1076-1086
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy
- 1 December 2019
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (12) , 1076-1086
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy
- 1 September 2019
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 50 (9) , e250-e256
Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes
BACKGROUND AND OBJECTIVE: Characterize eyes managed with quarterly intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration (nAMD). PATIENTS AND METHODS: Treatment-naïve nAMD eyes managed predominately using a treat-and-extend approach that received five or more consecutive quarterly injections from 2005 to 2017. RESULTS: One hundred fifty eyes were retrospectively identified. During quarterly dosing, a mean of 9.8 injections were given over a mean of 29 months. Ninety-one eyes (61%) had no exudative disease recurrence during quarterly dosing. Thirty-three eyes (22%) experienced exudative activity recurrence, with a mean cumulative yearly recurrence rate of 12% and a mean 6-letter loss of visual acuity (VA). Twenty-four eyes (16%) stopped quarterly treatments; nine (38%) of these subsequently experienced exudative activity recurrence with a mean 8-letter VA loss. CONCLUSION: In this real-world analysis of nAMD managed with quarterly dosing over a mean of more than 2 years' follow-up, 22% experienced disease recurrence during quarterly dosing, and 38% of eyes that stopped quarterly dosing experienced subsequent exudative disease recurrence. [ Ophthalmic Surg Lasers Imaging Retina . 2019;50:e250–e256.]
- 1 September 2019
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 50 (9) , e250-e256
Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes
BACKGROUND AND OBJECTIVE: Characterize eyes managed with quarterly intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration (nAMD). PATIENTS AND METHODS: Treatment-naïve nAMD eyes managed predominately using a treat-and-extend approach that received five or more consecutive quarterly injections from 2005 to 2017. RESULTS: One hundred fifty eyes were retrospectively identified. During quarterly dosing, a mean of 9.8 injections were given over a mean of 29 months. Ninety-one eyes (61%) had no exudative disease recurrence during quarterly dosing. Thirty-three eyes (22%) experienced exudative activity recurrence, with a mean cumulative yearly recurrence rate of 12% and a mean 6-letter loss of visual acuity (VA). Twenty-four eyes (16%) stopped quarterly treatments; nine (38%) of these subsequently experienced exudative activity recurrence with a mean 8-letter VA loss. CONCLUSION: In this real-world analysis of nAMD managed with quarterly dosing over a mean of more than 2 years' follow-up, 22% experienced disease recurrence during quarterly dosing, and 38% of eyes that stopped quarterly dosing experienced subsequent exudative disease recurrence. [ Ophthalmic Surg Lasers Imaging Retina . 2019;50:e250–e256.]
- Open Access
- 1 December 2018
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 49 (12) , 913-917
Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System
Ophthalmic Surgery, Lasers and Imaging Retina | Seenu M. Hariprasad Practical Retina Co-Editor For this Practical Retina column, Charles C. Wykoff, MD, PhD, and Brenda Zhou, BS, from Houston, Texas, were asked to comment on the innovations taking place to benefit our patients with neovascular AMD (nAMD). Retina specialists will agree that durability of our
- 1 December 2018
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 49 (12) , 913-917
Open AccessInnovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System
Ophthalmic Surgery, Lasers and Imaging Retina | Seenu M. Hariprasad Practical Retina Co-Editor For this Practical Retina column, Charles C. Wykoff, MD, PhD, and Brenda Zhou, BS, from Houston, Texas, were asked to comment on the innovations taking place to benefit our patients with neovascular AMD (nAMD). Retina specialists will agree that durability of our
- 19 February 2013
- Published by Springer Nature in Cell Research
- Vol. 23 (4) , 552-564
RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation
The PTEN tumor suppressor is a lipid phosphatase that has a central role in regulating the phosphatidylinositol-3-kinase (PI3K) signal transduction cascade. Nevertheless, the mechanism by which the PTEN activity is regulated in cells needs further elucidation. Although previous studies have shown that ubiquitination of PTEN can modulate its stability and subcellular localization, the role of ubiquitination in the most critical aspect of PTEN function, its phosphatase activity, has not been fully addressed. Here, we identify a novel E3 ubiquitin ligase of PTEN, Ret finger protein (RFP), that is able to promote atypical polyubiquitinations of PTEN. These ubiquitinations do not lead to PTEN instability or relocalization, but rather significantly inhibit PTEN phosphatase activity and therefore modulate its ability to regulate the PI3K signal transduction cascade. Indeed, RFP overexpression relieves PTEN-mediated inhibitory effects on AKT activation; in contrast, RNAi-mediated knockdown of endogenous RFP enhances the ability of PTEN to suppress AKT activation. Moreover, RFP-mediated ubiquitination of PTEN inhibits PTEN-dependent activation of TRAIL expression and also suppresses its ability to induce apoptosis. Our findings demonstrate a crucial role of RFP-mediated ubiquitination in controlling PTEN activity.
- 19 February 2013
- Published by Springer Nature in Cell Research
- Vol. 23 (4) , 552-564
RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation
The PTEN tumor suppressor is a lipid phosphatase that has a central role in regulating the phosphatidylinositol-3-kinase (PI3K) signal transduction cascade. Nevertheless, the mechanism by which the PTEN activity is regulated in cells needs further elucidation. Although previous studies have shown that ubiquitination of PTEN can modulate its stability and subcellular localization, the role of ubiquitination in the most critical aspect of PTEN function, its phosphatase activity, has not been fully addressed. Here, we identify a novel E3 ubiquitin ligase of PTEN, Ret finger protein (RFP), that is able to promote atypical polyubiquitinations of PTEN. These ubiquitinations do not lead to PTEN instability or relocalization, but rather significantly inhibit PTEN phosphatase activity and therefore modulate its ability to regulate the PI3K signal transduction cascade. Indeed, RFP overexpression relieves PTEN-mediated inhibitory effects on AKT activation; in contrast, RNAi-mediated knockdown of endogenous RFP enhances the ability of PTEN to suppress AKT activation. Moreover, RFP-mediated ubiquitination of PTEN inhibits PTEN-dependent activation of TRAIL expression and also suppresses its ability to induce apoptosis. Our findings demonstrate a crucial role of RFP-mediated ubiquitination in controlling PTEN activity.